Aarey Drugs Allots 1.15 Million Shares Upon Warrant Conversion

Shares allotted: 1,150,000 | Total funds raised: Rs 5.50 crore

Reader Takeaway: Equity base expands following warrant exercise while future dilution potential remains from remaining outstanding warrants.

What just happened

Aarey Drugs & Pharmaceuticals Ltd has formally allotted 1,150,000 equity shares to promoter and non-promoter entities. This follows the exercise of convertible warrants at a price of Rs 63.80 per share. The company has collected Rs 47.85 per warrant, amounting to a total inflow of Rs 5.50 crore. This action was authorized by the board following shareholder approval granted on January 2, 2025.

Why this matters

The conversion strengthens the company’s paid-up capital and provides liquidity for its operations. With the total share count rising from 30,724,303 to 31,874,303, existing shareholders should factor in the ongoing dilution as remaining warrants are exercised. This process is part of a larger plan initiated in May 2025 to raise capital via the issuance of 5,000,000 warrants.

What changes now

The company’s issued and paid-up capital has increased to Rs 31,874,3030. Of the initial 5,000,000 warrants, 3,520,000 have now been converted into equity. This leaves 1,480,000 warrants still eligible for conversion, providing a clear pipeline for future capital infusion into the business.

What to track next

Investors should monitor the remaining 1,480,000 warrants. These instruments carry an 18-month conversion window from the initial allotment date of May 23, 2025. Any further conversions will lead to additional equity expansion.